Danaher Corporation
Danaher Corporation Issues New Senior Notes for Masimo Acquisition and General Corporate Purposes
Summary
On April 29, 2026, Danaher Corporation issued €500 million of Floating Rate Senior Notes due 2028, €750 million of 3.250% Senior Notes due 2030, €750 million of 3.625% Senior Notes due 2034, and €1 billion of 4.000% Senior Notes due 2038. The notes were issued under an indenture dated December 11, 2007, as amended. Danaher intends to use the net proceeds from the sale of the notes to pay a portion of the cash consideration for, and certain costs associated with, the acquisition of Masimo Corporation. Danaher may also use a portion of the net proceeds for general corporate purposes, which may include refinancing of outstanding indebtedness, working capital, capital expenditures, and satisfaction of other obligations.
Profitelligence Alerts
Get alerts for DHR
Be first to know when Danaher Corporation files with the SEC.
Filing Categories
Advertisement
About Danaher Corporation
Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.
Official SEC Documents
Advertisement